Targeting oncoproteins for degradation by small molecules in myeloid leukemia-Reference-Cited by-同舟云学术

Targeting oncoproteins for degradation by small molecules in myeloid leukemia

Published:2017-12-04 Issue:10 Volume:59 Page:2297-2304
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Lei Hu¹^ORCID,Wang Weiwei¹,Wu Yingli¹

Affiliation:

1. Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1403600

Reference74 articles.

1. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

2. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

3. Acute myeloid leukaemia

4. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation

5. Midostaurin approved for FLT3-mutated AML

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. La technologie PROTAC;médecine/sciences;2024-03

2. The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions;Toxicology and Applied Pharmacology;2023-08

3. PROTAC: targeted drug strategy. Principles and limitations;Russian Chemical Bulletin;2022-11

4. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC;European Journal of Medicinal Chemistry;2019-11